Dechert Advises Medtech, Bertin Nahum, Newfund and Ally Bridge Group on Sale to Zimmer Biomet Holdings

Dechert LLP advised Medtech SA, and the main selling stockholders, Bertin Nahum, Newfund and Ally Bridge Group on the disposition to Zimmer Biomet. Medtech, founded in 2002, designs, develops, and markets robotic for brain surgery Rosa and applications to assist in surgical procedures, helping to create safer and more efficient, less invasive treatment.

Zimmer Biomet, a global leader in musculoskeletal healthcare, acquired 1,406,151 Medtech shares in the transaction, each share acquired at €50.00. The convertible bonds were acquired at a price of €50.03 per convertible bond and the warrants at a price of €17.17 per warrant. As part of the transaction, Zimmer Biomet will continue to maintain operations of Medtech in Montpellier, France.

The Dechert team advising the stockholders was led by corporate partner Matthieu Grollemund assisted by:

• Charles Cardon, national partner, Quentin Durand and Raphaël Sendowski, associates, on corporate aspects;
• Marianne Schaffner, partner, on Intellectual Property aspects;
• Mélanie Thill-Tayara, partner, on Antitrust/Competition aspects;
• Bruno Leroy, partner, on Tax aspects;
• Phillipe Thomas, Thomas Johnson (based in Philadelphia), partners, and Thibault Meiers, associate, on Employment aspects.

Read the official Press Release “Zimmer Biomet to acquire Medtech”.

Read the press release in French, "Dechert conseille Medtech, Bertin Nahum, Newfund et Ally Bridge Group dans sa cession à Zimmer Biomet Holdings."

About Dechert

Dechert is a global specialist law firm with a deep bench of experts focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients’ most important matters. Nothing stands in the way of giving clients the best of the firm’s entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.